Diuretic–gene interaction and the risk of myocardial infarction and stroke

被引:1
作者
H Schelleman
O H Klungel
J C M Witteman
M M B Breteler
A Hofman
C M van Duijn
A de Boer
B H Ch Stricker
机构
[1] Erasmus MC,Department of Epidemiology & Biostatistics
[2] Utrecht Institute for Pharmaceutical Sciences (UIPS),Department of Pharmacoepidemiology and Pharmacotherapy
[3] Utrecht University,undefined
来源
The Pharmacogenomics Journal | 2007年 / 7卷
关键词
pharmacogenetics; diuretics; polymorphisms; MI; stroke;
D O I
暂无
中图分类号
学科分类号
摘要
This study investigates whether the interaction between diuretics and alpha-adducin (ADD1) G460W or G-protein β3-subunit (GNB3) rs2301339 polymorphism modifies the risk of myocardial infarction (MI) or stroke. Data were used from the Rotterdam Study. The drug–gene interaction was determined with a Cox proportional hazard model with adjustment for each drug class as time-dependent covariates. The risk of MI in current users of low-ceiling diuretics with one or two copies of the ADD1 W-allele (hazard ration (HR)=0.92) was similar compared to the expected joint effect of the W-allele and low-ceiling diuretics on a multiplicative scale (1.04 × 0.90=0.94) (synergy index (SI):0.99; 95% confidence interval (CI): 0.43–2.27). No drug–gene interaction was found on the risk of stroke (SI:0.66; 95% CI:0.43–1.27). In addition, a trend towards an interaction was found between current use and the GNB3 rs230119 G/A polymorphism on the risk of MI (SI: 0.51; 95% CI: 0.23–1.15), whereas no interaction on the risk of stroke was found (SI: 0.84; 95% CI: 0.46–1.56).
引用
收藏
页码:346 / 352
页数:6
相关论文
共 77 条
[1]  
Whelton PK(1994)Epidemiology of hypertension Lancet 344 101-106
[2]  
MacMahon S(1990)Blood pressure, stroke, and coronary heart disease. Part prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias Lancet 335 765-774
[3]  
Peto R(1989)A prospective study of high blood pressure and cardiovascular disease in women Am J Epidemiol 130 646-654
[4]  
Cutler J(1992)Epidemiology and prevention of blood pressure-related renal disease J Hypertens Suppl 10 S77-S84
[5]  
Collins R(2000)Effects of ACE-inhibitors, calcium channel blockers, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Blood Pressure Lowering Treatment Trialists' Collaboration Lancet 356 1955-1964
[6]  
Sorlie P(1998)Alpha-adducin polymorphisms and renal sodium handling in essential hypertensive patients Kidney Int 53 1471-1478
[7]  
Neaton J(2002)Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension JAMA 287 1680-1689
[8]  
Fiebach NH(1997)Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension Lancet 349 1353-1357
[9]  
Hebert PR(1999)The role of alpha-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study Hypertension 34 649-654
[10]  
Stampfer MJ(2003)ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy Hypertension 41 398-403